NCT05132101View on ClinicalTrials.gov

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

CompletedOBSERVATIONAL
Enrollment

2,758

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Patients who received Palbociclib as first line therapy in MBC setting

Patients who received Palbociclib as first line therapy in MBC setting

Trial Locations (1)

Unknown

Pfizer Local Country Office, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05132101 - Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | Biotech Hunter | Biotech Hunter